Cytokinetics to Present at Healthcare Conferences in March
(Thomson Reuters ONE) -
South San Francisco, CA, February 24, 2015 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that Robert I. Blum, President and Chief Executive
Officer, is scheduled to present a corporate update at the following healthcare
conferences:
Cowen and Company 35(th) Annual Health Care Conference
Date: Tuesday, March 3, 2015
Time: 11:20 AM Eastern Time
Location: Boston Marriott Copley Place Hotel, Boston, MA
27(th) Annual ROTH Conference
Date: Monday, March 9, 2015
Time: 8:30 AM Pacific Time
Location: Ritz-Carlton, Laguna Nigel, Dana Point, CA
Interested parties may access the live audio of this presentation by visiting
the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The webcast replay of the presentation will be archived on
the Presentations page within the Investor Relations section of Cytokinetics'
website for two weeks following the completion of the event.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle
activator, as a potential treatment for amyotrophic lateral sclerosis (ALS).
Tirasemtiv has been granted orphan drug designation and fast track status by the
U.S. Food and Drug Administration and orphan medicinal product designation by
the European Medicines Agency for the potential treatment of ALS. Cytokinetics
is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle
activator, for the potential treatment of heart failure. Cytokinetics is
collaborating with Astellas Pharma Inc. to develop CK-2127107, a skeletal muscle
activator, for spinal muscular atrophy. Amgen holds an exclusive license
worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an
exclusive license worldwide to develop and commercialize CK-2127107. Both
licenses are subject to Cytokinetics' specified development and
commercialization participation rights. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell. Additional
information about Cytokinetics can be obtained at http://www.cytokinetics.com/.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but not
limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
Contacts:
Cytokinetics, Incorporated:
Joanna L. Goldstein
Manager, Investor Relations & Corporate Communications
(650) 624-3000
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via GlobeNewswire
[HUG#1896948]
Unternehmensinformation / Kurzprofil:
Datum: 24.02.2015 - 22:00 Uhr
Sprache: Deutsch
News-ID 373985
Anzahl Zeichen: 5172
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics to Present at Healthcare Conferences in March"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
